Neurocrine officer sells shares after option exercise
Neurocrine Biosciences Chief Regulatory Officer Ingrid Delaet reported a series of option exercises and related stock sales in early July.
Rhea-AI Filing Summary
Neurocrine Biosciences Chief Regulatory Officer Ingrid Delaet reported a series of option exercises and related stock sales in early July. She exercised stock options covering 14,571 shares of common stock at an exercise price of $103.52 per share, then sold an equal number of shares in open-market transactions at weighted average prices around $178.55–$178.72 per share.
The transactions on July 7–9, 2026 were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026. Following these trades, Delaet directly owns 16,225 shares of Neurocrine Biosciences common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 14,571 shares ($1.09M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Delaet Ingrid
Role
Chief Regulatory Officer
Sold
14,571 shs ($2.60M)
Approx. gross sale proceeds
$2.60M
Approx. exercise cost
$1.51M
Approx. pre-tax spread
$1.09M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option | 8,433 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,433 | $103.52 | $873K |
| Sale | Common Stock | 8,433 | $178.7187 | $1.51M |
| Exercise | Non-Qualified Stock Option | 2,737 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,737 | $103.52 | $283K |
| Sale | Common Stock | 2,737 | $178.543 | $489K |
| Exercise | Non-Qualified Stock Option | 3,401 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,401 | $103.52 | $352K |
| Sale | Common Stock | 3,401 | $178.5666 | $607K |
Holdings After Transaction:
Non-Qualified Stock Option — 7,478 contracts (Direct);
Common Stock — 16,225 shares (Direct)
Footnotes (5)
- F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.
Key Figures
Shares sold total: 14,571 shares
Sale price July 9: $178.7187 per share
Sale price July 8: $178.5430 per share
+5 more
8 metrics
Shares sold total
14,571 shares
Open-market sales on July 7–9, 2026
Sale price July 9
$178.7187 per share
8,433 shares of common stock sold
Sale price July 8
$178.5430 per share
2,737 shares of common stock sold
Sale price July 7
$178.5666 per share
3,401 shares of common stock sold
Option exercise price
$103.52 per share
Non-qualified stock options exercised for 14,571 shares
Post-transaction holdings
16,225 shares
Common stock held directly after transactions
Option expiration
February 13, 2033
Non-qualified stock options on Neurocrine common stock
10b5-1 plan adoption
February 27, 2026
Date Ingrid Delaet adopted trading plan
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price per share, Chief Regulatory Officer, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option" with an expiration date of 2033-02-13"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Chief Regulatory Officer financial
"officer_title: "Chief Regulatory Officer" for reporting person Ingrid Delaet"
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for the option-related transactions coded M"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Neurocrine Biosciences (NBIX) executive Ingrid Delaet report in this Form 4?
Ingrid Delaet reported exercising stock options for 14,571 Neurocrine Biosciences shares and selling the same number in open-market trades. These transactions occurred over July 7–9, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan.
What stock options did Ingrid Delaet exercise in Neurocrine Biosciences (NBIX)?
Delaet exercised non-qualified stock options covering 14,571 underlying Neurocrine Biosciences shares at an exercise price of $103.52 per share. The option grant was dated February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.
Was Ingrid Delaet’s Neurocrine Biosciences (NBIX) stock sale part of a 10b5-1 trading plan?
Yes. The disposition was executed by a broker under a Rule 10b5-1 trading plan adopted by Ingrid Delaet on February 27, 2026. Company policy restricts her from amending or modifying this trading plan after its adoption, indicating the sales were pre-planned.
When do Ingrid Delaet’s exercised Neurocrine Biosciences (NBIX) options expire?
The non-qualified stock options exercised by Ingrid Delaet, which relate to Neurocrine Biosciences common stock, have an expiration date of February 13, 2033. They were originally granted on February 13, 2023 and vest in 48 equal monthly installments starting March 13, 2023.
AI-generated analysis. How Rhea-AI works. Not financial advice.
